Exelixis | EXEL - Ebit

Aktienkurs
47.78
Täglich Wechseln
1.57 3.40%
Monatlich
5.22%
Jährlich
32.10%
Q2 Prognose
42.77




Ebit Veränderung Datum
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Amgen USD 3.83B 130M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
Bayer EUR 1.11B 1.51B 2025-12
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 3.56B 90M 2026-03
Cytokinetics USD -181.23M 2.86M 2026-03
Eisai JPY 20.03B 6.36B 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Exelixis USD 251.34M 15.43M 2026-03
Genmab DKK 260M 199M 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Incyte USD 344.17M 39.71M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
MacroGenics USD -12.1M 32.26M 2025-12
Merck USD -1.88B 8.12B 2026-03
Moderna USD -1.39B 531M 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Novartis USD 4.18B 118M 2026-03
Pfizer USD 4.99B 340M 2026-03
Puma Biotechnology USD -2.2M 11.41M 2024-06
Sanofi EUR 3.74B 2.23B 2025-09
Takeda JPY 257.49B 568.56B 2025-12
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Xencor USD -77.86M 24.23M 2026-03